Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and nicotine predict medication efficacy and adverse events. Subjects participated in randomized, double-blind, placebo-controlled smoking cessation clinical trials, comparing varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor, and placebo. Primary analysis included 1175 smokers of European ancestry, and 785 single nucleotide polymorphisms from 24 genes, representing 254 linkage disequilibrium (LD) bins (genes included nAChR subunits, additional varenicline-specific genes, and genes involved in nicotine or bupropion metabolism). For varenicline, continuous abstinence (weeks 9-12) was associated with multiple nAChR subunit genes (including CHRNB2, CHRNA5, and CHRNA4) (OR=1.76; 95% CI: 1.23-2.52) (p<0.005); for bupropion, abstinence was associated with CYP2B6 (OR=1.78; 95% CI: 1.27-2.50) (p<0.001). Incidence of nausea was associated with several nAChR subunit genes (OR=0.50; 95% CI: 0.36-0.70) (p<0.0001) and time to relapse after quitting was associated with HTR3B (HR=1.97; 95% CI: 1.45-2.68) (p<0.0001). These data provide evidence for multiple genetic loci contributing to smoking cessation and therapeutic response. Different loci are associated with varenicline vs bupropion response, suggesting that additional research may identify clinically useful markers to guide treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Practice Guideline: Otitis Media with Effusion (Update)
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., et al. (2016) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815623467 · Cited by 2,006
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 6×
“The CPD association with the 15q25 region was detected in this population despite the absence of a full range of smoking phenotypes (individuals smoking o10 CPD were excluded from the clinical trials) (Gonzales et al, 2006; Jorenby et al, 2006; Oncken et al, 2006).”
BackgroundMethodInfluentialA variant associated with nicotine dependence, lung cancer and peripheral arterial disease
Thorgeirsson, T. E., Geller, F., Sulem, P., Rafnar, T., Wiste, A., Magnusson, K. P., Manolescu, A., Thorleifsson, G., Stefansson, H., Ingason, A., et al. (2008) · Nature · doi:10.1038/nature06846 · Cited by 1,523 · cited 8×
“Figure 2 shows the time to relapse associated with the two most predictive SNPs, rs11606194 and rs3758987.”
BackgroundMethodResultInfluentialGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 5×
“The CPD association with the 15q25 region was detected in this population despite the absence of a full range of smoking phenotypes (individuals smoking o10 CPD were excluded from the clinical trials) (Gonzales et al, 2006; Jorenby et al, 2006; Oncken et al, 2006).”
BackgroundMethodInfluentialAmos, C. I., Wu, X., Broderick, P., Gorlov, I. P., Gu, J., Eisen, T., Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., et al. (2008) · Nature Genetics · doi:10.1038/ng.109 · Cited by 1,310
Hung, R. J., McKay, J. D., Gaborieau, V., Boffetta, P., Hashibe, M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissowska, J., Rudnai, P., et al. (2008) · Nature · doi:10.1038/nature06885 · Cited by 1,275 · cited 3×
“The relevance of the association with the CHRNA7 locus is less clear, although varenicline does bind to homopentameric a7 nicotinic receptors (Coe et al, 2005), however with reduced affinity in comparison with a4b2 receptors (Amos et al, 2008; Hung et al, 2008; Thorgeirsson et al, 2008).”
BackgroundGenome-wide meta-analyses identify multiple loci associated with smoking behavior
The Tobacco and Genetics Consortium (2010) · Nature Genetics · doi:10.1038/ng.571 · Cited by 1,098
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics
Benowitz, N. L. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094742 · Cited by 979 · cited 1×
“In addition, several pharmacogenomics studies have investigated the effect of nicotine metabolism rates directly, through analysis of nicotine metabolites (Benowitz, 2009) with reproducible associations with smoking cessation (Ray et al, 2009).”
BackgroundSelf-citationVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 2×
“The relevance of the association with the CHRNA7 locus is less clear, although varenicline does bind to homopentameric a7 nicotinic receptors (Coe et al, 2005), however with reduced affinity in comparison with a4b2 receptors (Amos et al, 2008; Hung et al, 2008; Thorgeirsson et al, 2008).”
BackgroundBrain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior
The ENGAGE Consortium, Thorgeirsson, T. E., Gudbjartsson, D. F., Surakka, I., Vink, J. M., Amin, N., Geller, F., Sulem, P., Rafnar, T., Esko, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.573 · Cited by 689 · cited 11×
“Incidence of nausea was associated with several nAChR subunit genes (OR¼ 0.50; 95% CI: 0.36–0.70) (po0.”
BackgroundMethodInfluentialSelf-citationHabenular α5 nicotinic receptor subunit signalling controls nicotine intake
Fowler, C. D., Lu, Q., Johnson, P. M., Marks, M. J., & Kenny, P. J. (2011) · Nature · doi:10.1038/nature09797 · Cited by 663 · cited 1×
“Neuropsychopharmacology dependence (Fowler et al, 2011; Kuryatov et al, 2011; Zheng et al, 2011).”
Saccone, N. L., Culverhouse, R. C., Schwantes-An, T.-H., Cannon, D. S., Chen, X., Cichon, S., Giegling, I., Han, S., Han, Y., Keskitalo-Vuokko, K., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001053 · Cited by 395 · cited 3×
“The potential role of CHRN10A in smoking cessation is less clear, although it has been shown recently to be associated with nicotine dependence in an African-American population (Saccone et al, 2010a, b).”
BackgroundSelf-citationOncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
Saccone, N. L., Saccone, S. F., Hinrichs, A. L., Stitzel, J. A., Duan, W., Pergadia, M. L., Agrawal, A., Breslau, N., Grucza, R. A., Hatsukami, D., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30828 · Cited by 215 · cited 2×
“A better understanding of these associations may come from the identification and characterization of additional functional alleles affecting CYP2B6 activity or expression.”
BackgroundSelf-citationDefining nicotine dependence for genetic research: evidence from Australian twins
LESSOV, C. N., MARTIN, N. G., STATHAM, D. J., TODOROV, A. A., SLUTSKE, W. S., BUCHOLZ, K. K., HEATH, A. C., & MADDEN, P. A. F. (2004) · Psychological Medicine · doi:10.1017/s0033291703001582 · Cited by 185 · cited 1×
“%) of the likelihood of quitting is genetic in origin (Broms et al, 2006; Lessov et al, 2004; Xian et al, 2003), suggesting that specific genetic risk factors could be identified.”
BackgroundKuryatov, A., Berrettini, W., & Lindstrom, J. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.066357 · Cited by 171 · cited 1×
“Neuropsychopharmacology dependence (Fowler et al, 2011; Kuryatov et al, 2011; Zheng et al, 2011).”
Xian, H., Scherrer, J. F., Madden, P. A. F., Lyons, M. J., Tsuang, M., True, W. R., & Eisen, S. A. (2003) · Nicotine & Tobacco Research · doi:10.1080/1462220031000073667 · Cited by 138
Conti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., Bergen, A. W., Swan, G. E., Tyndale, R. F., Benowitz, N. L., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn181 · Cited by 136 · cited 3×
“…determinants of smoking cessation, recent pharmacogenetic studies have investigated genes that may impact nicotine or bupropion activity and metabolism, and also components of the dopaminergic system related to addiction (Conti et al, 2008; Kortmann et al, 2010; Lee et al, 2007; Ray et al, 2010).”
BackgroundSelf-citationHow does bupropion work as a smoking cessation aid?
Warner, C., & Shoaib, M. (2005) · Addiction Biology · doi:10.1080/13556210500222670 · Cited by 115 · cited 1×
“Bupropion is a dopamine/norepinephrine reuptake inhibitor that also acts as a nicotinic receptor antagonist (Warner and Shoaib, 2005); varenicline is a partial agonist of the a4b2 nAChR subtype (Coe et al, 2005).”
BackgroundSerotonin Type 3 Receptor Genes: HTR3A, B, C, D, E
Niesler, B., Kapeller, J., Hammer, C., & Rappold, G. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.501 · Cited by 78 · cited 1×
“These genes were originally included in our study to test whether they might be related to nausea associated with varenicline treatment, although they are expressed widely in the brain as well as the gut (Niesler et al, 2008).”
BackgroundPerkins, K. A., Lerman, C., Mercincavage, M., Fonte, C. A., & Briski, J. L. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0166 · Cited by 42
Self-citation
Cited by
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
McLaughlin, I., Dani, J. A., & De Biasi, M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/978-3-319-13482-6_4 · Cited by 191
A CHRNA5 smoking risk variant decreases the aversive effects of nicotine in humans
Jensen, K. P., DeVito, E. E., Herman, A. I., Valentine, G. W., Gelernter, J., & Sofuoglu, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.131 · Cited by 85
Antidepressants for smoking cessation
Hajizadeh, A., Howes, S., Theodoulou, A., Klemperer, E., Hartmann-Boyce, J., Livingstone-Banks, J., & Lindson, N. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub6 · Cited by 84
Metadata
- Authors
- King, D. P., Paciga, S., Pickering, E., Benowitz, N. L., Bierut, L. J., Conti, D. V., Kaprio, J., Lerman, C., & Park, P. W.
- Venue
- Neuropsychopharmacology
- Published
- 2011-11-02
- Volume
- 37
- Issue
- 3
- Pages
- 641-650
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2049001747
- Cited by
- 120
- References
- 22
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.